Company intelligence / Profile preview
Highlight Therapeutics
Paterna, Comunidad Valenciana / Valencian Community, Spainhighlighttherapeutics.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Lead candidate BO‑112 has shown the ability to initiate a strong immune response against tumors by making them more visible to the immune system. It has demonstrated potential both as monotherapy and in combination with checkpoint inhibitors, especially for patients resistant to current therapies. Clinical trials are ongoing or recently completed in basal cell carcinoma and other solid tumors. No active trials currently listed on ClinicalTrials.gov as of latest check.
- Therapeutic areas
- Oncology
- Modalities
- RNA-based therapies (specifically intra-lesional RNA-based therapy)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Merck & Co.UCLA
Beyond the preview
Go deeper on Highlight Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Highlight Therapeutics.